Abstract
Cerebrolysin® is a peptidergic drug which displays neurotrophic action in various animal models. It is used for the treatment of dementia and in this report we provide evidence for the long-term clinical efficacy of Cerebrolysin® in Alzheimer’s disease. This evidence is based on our clinical experience with Cerebrolysin®, stemming from our participation in a double- blind, placebo-controlled clinical trial, a compassionate use programme initiated thereafter, and a PET study. Our data suggests, that Cerebrolysin® is a safe and effective treatment for Alzheimer’s disease and that repeat treatments may maintain function in patients over the long-term.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Ioku M, Hashimoto S (1992) Neurotrophic factor like effect of FPF1070 on septal cholinergic neurons after transection of fimbria-fornix in the rat brain. Histol Histopathol 7: 213 – 221
Francis-Turner L, Valouskova V (1996) Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transsection: Short-term study. Neurosci Lett 202: 193 – 196
Hefti FL, Schneider S (1991) Nerve growth factor and Alzheimer’s disease. Clin Neuropharmacol 14: 62 – 76
Olson L, Nordberg A, von Hoist H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, Herlitz A, Lilja A, et al (1992) Nerve growth factor affects HC-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 4 (1): 79 – 95
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, et al (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136 – 145
Ruther W, Ritter R, Apecechea M, Freytag S, Windisch M (1994) Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 27: 32 – 40
Tuszynski MH, Gage FH (1990) Potential use of neurotrophic agents in the treatment of neurodegenerative disorders. Acta Neurobiol Exp 50: 323 – 332
Windisch M, Albrecht E, Eggenreich U, Paier B (1993) Neurotrophic effects of the nootropic drug Cerebrolysin — A summary. In: Nicolini M, Zatta PF, Corain B (eds) Advances in the biosciences, vol. 87, Pergamon Press, Oxford, 355 – 357
Windisch M, Piswanger A (1987) EinfluB einer 7tagigen Behandlung mit Cerebrolysin auf die Atmung von Hirnmitochondrien. Neuropsychiatrie 1 (2): 83 – 88
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag/Wien
About this paper
Cite this paper
Molloy, W., Standish, T.I. (2000). Clinical experience with Cerebrolysin®. In: Jellinger, K., Schmidt, R., Windisch, M. (eds) Advances in Dementia Research. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6781-6_31
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6781-6_31
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83512-8
Online ISBN: 978-3-7091-6781-6
eBook Packages: Springer Book Archive